首页> 外文OA文献 >In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system
【2h】

In vivo biodistribution, anti-inflammatory, and hepatoprotective effects of liver targeting dexamethasone acetate loaded nanostructured lipid carrier system

机译:肝靶向醋酸地塞米松负载纳米结构脂质载体系统的体内生物分布,抗炎和保肝作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We aimed to evaluate whether the enhancement of the liver accumulation and anti-inflammatory activity of dexamethasone acetate (DXMA) could be achieved by incorporating it into nanostructured lipid carrier (NLCs). DXMA-NLCs were prepared using a film dispersion-ultrasonication method and characterized in terms of particle size, PDI, zeta potential, differential scanning calorimetry, drug loading capacity, encapsulation efficiency, and in vitro release. The biodistribution and pharmacokinetics of DXMA-NLCs in mice were significantly different from those of the DXMA solution (DXMA-sol). The peak concentration of DXMA-NLCs was obtained half an hour after intravenous administration. More than 55.62% of the total administrated dose was present in the liver. An increase of 2.57 fold in the area under the curve was achieved when compared with that of DXMA-sol. DXMA-NLCs exhibited a significant anti-inflammatory and hepatoprotective effect on carrageenan-induced rats and carbon tetrachloride-induced mice compared with DXMA-sol. However, the effect was not in proportion to the dosage. The intermediate and low dosages presented better effects than DXMA-sol. All results indicate that NLCs, as a novel carrier for DXMA, has potential for the treatment of liver diseases, increasing the cure efficiency and decreasing the side effects on other tissues.
机译:我们旨在评估是否可以通过将其纳入纳米结构脂质载体(NLCs)中来增强醋酸地塞米松(DXMA)的肝脏蓄积和抗炎活性。 DXMA-NLC使用膜分散超声方法制备,并通过粒径,PDI,ζ电位,差示扫描量热法,载药量,包封效率和体外释放进行表征。 DXMA-NLC在小鼠中的生物分布和药代动力学显着不同于DXMA溶液(DXMA-sol)。静脉内给药半小时后,获得DXMA-NLC的峰值浓度。肝脏中占总给药剂量的55.62%以上。与DXMA-sol相比,曲线下面积增加了2.57倍。 DXMA-NLC与DXMA-sol相比,对角叉菜胶诱导的大鼠和四氯化碳诱导的小鼠表现出显着的抗炎和保肝作用。但是,效果与剂量不成比例。中剂量和低剂量比DXMA-sol具有更好的效果。所有结果表明,NLC作为DXMA的新型载体,具有治疗肝脏疾病的潜力,可提高治愈效率并减少对其他组织的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号